---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-034976"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:19:14.461225+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Bioventus Q2 revenue up 10.3% (organic +13.9%); raises FY2024 guidance

## Summary
- Revenue $151.2M (+10.3% YoY); Pain Treatments +17.2%, Surgical Solutions +18.6% US.
- Net loss from continuing operations $32.1M vs $4.7M, including $31.9M impairment and litigation settlement.
- Adjusted EBITDA $34.5M (+22.4% YoY); non-GAAP EPS $0.19 vs $0.14.
- Raising FY2024 guidance: revenue $557-567M, adjusted EBITDA $104-107M, non-GAAP EPS $0.36-0.42.
- FDA clearance for OSTEOAMP Cannula; pursuing divestiture of Advanced Rehabilitation to reduce debt.

## SEC filing metadata
- accession: 0001628280-24-034976
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000162828024034976/0001628280-24-034976-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000162828024034976/bvs-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-034976
- JSON: https://secwatch.observer/filing/0001628280-24-034976.json
- Plain text: https://secwatch.observer/filing/0001628280-24-034976.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.